[go: up one dir, main page]

CL2009001856A1 - Suspension farmaceutica submicronica que comprende el agente terapeutico nepafenac, un polimero cargado de bajo peso molecular y uno o mas excipientes; metodo de preparacion, util para administrar ocularmente. - Google Patents

Suspension farmaceutica submicronica que comprende el agente terapeutico nepafenac, un polimero cargado de bajo peso molecular y uno o mas excipientes; metodo de preparacion, util para administrar ocularmente.

Info

Publication number
CL2009001856A1
CL2009001856A1 CL2009001856A CL2009001856A CL2009001856A1 CL 2009001856 A1 CL2009001856 A1 CL 2009001856A1 CL 2009001856 A CL2009001856 A CL 2009001856A CL 2009001856 A CL2009001856 A CL 2009001856A CL 2009001856 A1 CL2009001856 A1 CL 2009001856A1
Authority
CL
Chile
Prior art keywords
therapeutic agent
useful
nepafenac
submicron
excipients
Prior art date
Application number
CL2009001856A
Other languages
English (en)
Inventor
Bahram Asgharian
Ernesto J Castillo
Masood A Chowhan
Original Assignee
Alcon Res Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41353867&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2009001856(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alcon Res Ltd filed Critical Alcon Res Ltd
Publication of CL2009001856A1 publication Critical patent/CL2009001856A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

LA PRESENTE INVENCIÓN ESTÁ DIRIGIDA A UNA SUSPENSIÓN SUBMICRÓNICA FARMACÉUTICA Y A UN MÉTODO PARA LA FORMACIÓN DE LA SUSPENSIÓN SUBMICRÓNICA. LA SUSPENSIÓN SUBMICRÓNICA ES ÚTIL PARA LA ENTREGA DE UN AGENTE TERAPÉUTICO RELATIVAMENTE HIDRÓFOBO Y/O DE BAJA SOLUBILIDAD. LA SUSPENSIÓN SUBMICRÓNICA Y EL MÉTODO PARA LA FORMACIÓN DE LA SUSPENSIÓN SUBMICRÓNICA, EMPLEA, TÍPICAMENTE, UN MATERIAL POLÍMERO QUE AYUDA EN LA PREVENCIÓN DE LA AGREGACIÓN DEL AGENTE TERAPÉUTICO.        
CL2009001856A 2008-09-19 2009-09-15 Suspension farmaceutica submicronica que comprende el agente terapeutico nepafenac, un polimero cargado de bajo peso molecular y uno o mas excipientes; metodo de preparacion, util para administrar ocularmente. CL2009001856A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US9828008P 2008-09-19 2008-09-19

Publications (1)

Publication Number Publication Date
CL2009001856A1 true CL2009001856A1 (es) 2010-12-31

Family

ID=41353867

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2009001856A CL2009001856A1 (es) 2008-09-19 2009-09-15 Suspension farmaceutica submicronica que comprende el agente terapeutico nepafenac, un polimero cargado de bajo peso molecular y uno o mas excipientes; metodo de preparacion, util para administrar ocularmente.

Country Status (26)

Country Link
US (3) US20100076045A1 (es)
EP (2) EP2425815B1 (es)
JP (3) JP5739809B2 (es)
KR (1) KR101682924B1 (es)
CN (2) CN102176898A (es)
AR (2) AR073597A1 (es)
AU (1) AU2009293400B2 (es)
BR (1) BRPI0919199B8 (es)
CA (1) CA2736106C (es)
CL (1) CL2009001856A1 (es)
CY (1) CY1119740T1 (es)
DK (1) DK2425815T3 (es)
ES (2) ES2592503T3 (es)
HR (1) HRP20180050T1 (es)
HU (1) HUE037933T2 (es)
LT (1) LT2425815T (es)
MX (1) MX348204B (es)
NO (1) NO2425815T3 (es)
PL (2) PL2328551T3 (es)
PT (2) PT2328551T (es)
RU (1) RU2521258C2 (es)
SI (1) SI2425815T1 (es)
TW (1) TWI580441B (es)
UY (1) UY32095A (es)
WO (1) WO2010033528A1 (es)
ZA (1) ZA201101398B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070202186A1 (en) 2006-02-22 2007-08-30 Iscience Interventional Corporation Apparatus and formulations for suprachoroidal drug delivery
WO2010103120A1 (en) * 2009-03-12 2010-09-16 Medichem, S.A. New crystals of a benzoylbenzeneacetamide derivative
CN103327939B (zh) 2010-10-15 2017-05-24 科尼尔赛德生物医学公司 用于进入眼睛的装置
CA2820178A1 (en) * 2010-12-06 2012-06-14 Degama Berrier Ltd. Composition and method for improving stability and extending shelf life of probiotic bacteria and food products thereof
US9827191B2 (en) 2012-05-03 2017-11-28 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
US20130316001A1 (en) * 2012-05-03 2013-11-28 Kala Pharmaceuticals, Inc. Particles, compositions and methods for ophthalmic and/or other applications
WO2013166408A1 (en) 2012-05-03 2013-11-07 Kala Pharmaceuticals, Inc. Pharmaceutical nanoparticles showing improved mucosal transport
US11596599B2 (en) 2012-05-03 2023-03-07 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
WO2013166385A1 (en) 2012-05-03 2013-11-07 Kala Pharmaceuticals, Inc. Pharmaceutical nanoparticles showing improved mucosal transport
EP2934484A1 (en) * 2012-12-19 2015-10-28 Kashiv Pharma, LLC Supersaturated stabilized nanoparticles for poorly soluble drugs
JP6669499B2 (ja) 2013-02-15 2020-03-18 カラ ファーマシューティカルズ インコーポレイテッド 治療用化合物
WO2014130612A1 (en) 2013-02-20 2014-08-28 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
MX372859B (es) 2013-05-03 2020-07-07 Clearside Biomedical Inc Aparatos y métodos para inyección ocular.
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
CN108530458A (zh) 2013-11-01 2018-09-14 卡拉制药公司 治疗化合物的结晶形式及其用途
WO2016036588A1 (en) * 2014-09-03 2016-03-10 Merck Sharp & Dohme Corp. Pharmaceutical suspensions containing etoricoxib
CA3062845A1 (en) 2016-05-02 2017-11-09 Clearside Biomedical, Inc. Systems and methods for ocular drug delivery
IL305537B2 (en) 2016-08-12 2025-02-01 Clearside Biomedical Inc Devices and methods for adjusting the insertion depth of a needle for administering a drug
EP3509423A4 (en) 2016-09-08 2020-05-13 Kala Pharmaceuticals, Inc. CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF
AU2017324713B2 (en) 2016-09-08 2020-08-13 KALA BIO, Inc. Crystalline forms of therapeutic compounds and uses thereof
EP3509421A4 (en) 2016-09-08 2020-05-20 Kala Pharmaceuticals, Inc. CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF
CA3037174A1 (en) * 2016-09-16 2018-03-22 Kala Pharmaceuticals, Inc. Particles, compositions, and methods for ophthalmic and/or other applications
TW202103707A (zh) * 2019-04-16 2021-02-01 美商克利爾斯德生物醫學公司 注射用安西諾隆（ｔｒｉａｍｃｉｎｏｌｏｎｅ）調配物
WO2025183017A1 (ja) * 2024-02-26 2025-09-04 大塚製薬株式会社 Ｑｕａｂｏｄｅｐｉｓｔａｔ含有組成物

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5466680A (en) * 1992-03-26 1995-11-14 Cytologics, Inc. Method and compositions for enhancing white blood cell functioning on a mucosal or cutaneous surface
ES2079994B1 (es) 1992-10-07 1996-08-01 Cusi Lab Formulacion farmaceutica a base de polimixina-trimetoprim y un agente antiinflamatorio para su utilizacion topica oftalmica y otica.
US5298262A (en) * 1992-12-04 1994-03-29 Sterling Winthrop Inc. Use of ionic cloud point modifiers to prevent particle aggregation during sterilization
US5429824A (en) * 1992-12-15 1995-07-04 Eastman Kodak Company Use of tyloxapole as a nanoparticle stabilizer and dispersant
WO1995005803A1 (en) * 1993-08-20 1995-03-02 Alcon Laboratories, Inc. Topical ophthalmic pharmaceutical vehicles
US5718919A (en) * 1995-02-24 1998-02-17 Nanosystems L.L.C. Nanoparticles containing the R(-)enantiomer of ibuprofen
US6969529B2 (en) * 2000-09-21 2005-11-29 Elan Pharma International Ltd. Nanoparticulate compositions comprising copolymers of vinyl pyrrolidone and vinyl acetate as surface stabilizers
US6428814B1 (en) * 1999-10-08 2002-08-06 Elan Pharma International Ltd. Bioadhesive nanoparticulate compositions having cationic surface stabilizers
US6375986B1 (en) * 2000-09-21 2002-04-23 Elan Pharma International Ltd. Solid dose nanoparticulate compositions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate
CN1211164C (zh) * 2000-05-10 2005-07-20 斯凯伊药品加拿大公司 介质研磨
PE20020146A1 (es) * 2000-07-13 2002-03-31 Upjohn Co Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2)
RU2219910C2 (ru) * 2002-01-08 2003-12-27 Институт органической и физической химии им. А.Е.Арбузова КНЦ РАН Ветеринарный имплантируемый препарат иммуностимулирующего действия (варианты)
US7138468B2 (en) * 2002-03-27 2006-11-21 University Of Southern Mississippi Preparation of transition metal nanoparticles and surfaces modified with (CO)polymers synthesized by RAFT
CA2492488A1 (en) * 2002-07-16 2004-01-22 Elan Pharma International, Ltd. Liquid dosage compositions of stable nanoparticulate active agents
CA2513006A1 (en) * 2003-01-15 2004-08-05 Dow Global Technologies Inc. Drug particles obtained by freezing onto a cold surface
US20040235892A1 (en) 2003-05-22 2004-11-25 Yujia Dai Indazole and benzisoxazole kinase inhibitors
AU2004277864A1 (en) * 2003-09-23 2005-04-14 Alcon, Inc. Triamcinolone acetonide and anecortave acetate formulations for injection
US20060141049A1 (en) * 2003-11-12 2006-06-29 Allergan, Inc. Triamcinolone compositions for intravitreal administration to treat ocular conditions
WO2005072710A2 (en) * 2004-01-28 2005-08-11 Johns Hopkins University Drugs and gene carrier particles that rapidly move through mucous barriers
WO2006043172A1 (en) * 2004-10-19 2006-04-27 Pfizer Inc. Pharmaceutical compositions and methods for sub-tenon delivery
WO2006062875A1 (en) * 2004-12-08 2006-06-15 Merck & Co., Inc. Ophthalmic nanoparticulate formulation of a cyclooxygenase-2 selective inhibitor
TW200640443A (en) * 2005-02-23 2006-12-01 Alcon Inc Methods for treating ocular angiogenesis, retinal edema, retinal ischemia, and diabetic retinopathy using selective RTK inhibitors
EP1871345B1 (en) * 2005-04-12 2012-08-01 Elan Pharma International Limited Nanoparticulate erlotinib formulations
WO2006109177A1 (en) * 2005-04-13 2006-10-19 Pfizer Products Inc. Injectable depot formulations and methods for providing sustained release of poorly soluble drugs comprising nanoparticles
US7893040B2 (en) * 2005-07-22 2011-02-22 Oculis Ehf Cyclodextrin nanotechnology for ophthalmic drug delivery
JP5112669B2 (ja) * 2005-09-30 2013-01-09 富山化学工業株式会社 難溶性薬物のナノ微粒子を含有する水性懸濁液剤
WO2007076448A2 (en) * 2005-12-23 2007-07-05 Alcon, Inc. Pharmaceutical composition for delivery of receptor tyrosine kinase inhibiting (rtki) compounds to the eye
US20070196350A1 (en) * 2006-02-22 2007-08-23 Bartels Stephen P Compositions and Methods for Effecting Controlled Posterior Vitreous Detachment

Also Published As

Publication number Publication date
CN102176898A (zh) 2011-09-07
KR101682924B1 (ko) 2016-12-06
EP2328551B1 (en) 2016-06-15
KR20110054055A (ko) 2011-05-24
RU2011115211A (ru) 2012-10-27
HRP20180050T1 (hr) 2018-02-09
EP2425815B1 (en) 2017-10-25
AU2009293400A1 (en) 2010-03-25
CY1119740T1 (el) 2018-09-05
JP5739809B2 (ja) 2015-06-24
PL2328551T3 (pl) 2017-04-28
US20170216228A1 (en) 2017-08-03
BRPI0919199B1 (pt) 2020-10-27
MX2011002494A (es) 2011-04-07
JP2017043637A (ja) 2017-03-02
NO2425815T3 (es) 2018-03-24
AR073597A1 (es) 2010-11-17
ZA201101398B (en) 2012-04-25
WO2010033528A1 (en) 2010-03-25
PL2425815T3 (pl) 2018-03-30
CA2736106C (en) 2016-08-16
PT2425815T (pt) 2018-01-31
ES2657455T3 (es) 2018-03-05
BRPI0919199B8 (pt) 2021-05-25
US20100076045A1 (en) 2010-03-25
CN104688682A (zh) 2015-06-10
EP2328551A1 (en) 2011-06-08
BRPI0919199A2 (pt) 2015-12-15
RU2521258C2 (ru) 2014-06-27
ES2592503T3 (es) 2016-11-30
SI2425815T1 (en) 2018-02-28
MX348204B (es) 2017-05-30
TWI580441B (zh) 2017-05-01
EP2425815A1 (en) 2012-03-07
DK2425815T3 (da) 2018-01-29
UY32095A (es) 2010-01-29
CA2736106A1 (en) 2010-03-25
TW201014612A (en) 2010-04-16
AR124648A2 (es) 2023-04-19
PT2328551T (pt) 2016-09-22
AU2009293400B2 (en) 2015-05-07
JP2012503003A (ja) 2012-02-02
HUE037933T2 (hu) 2018-09-28
HK1152258A1 (zh) 2012-02-24
JP2015052020A (ja) 2015-03-19
LT2425815T (lt) 2018-01-25
US20140294970A1 (en) 2014-10-02

Similar Documents

Publication Publication Date Title
CL2009001856A1 (es) Suspension farmaceutica submicronica que comprende el agente terapeutico nepafenac, un polimero cargado de bajo peso molecular y uno o mas excipientes; metodo de preparacion, util para administrar ocularmente.
CL2019003433A1 (es) Composición farmacéutica oftálmica que comprende nanopartículas mucopenetrantes, cuyo núcleo comprende un agente activo farmacéutico seleccionado entre un inhibidor de receptor tirosina quinasa (rtk), o un inhibidor de la angiogénesis, y está recubierto con un polímero modificador de superficie; y uso para tratar un trastorno del ojo (divisional de solicitud cl 2956-2014).
Irache et al. Nanomedicine: novel approaches in human and veterinary therapeutics
CO2022002685A2 (es) Nanopartículas lipídicas mejoradas para el suministro de ácidos nucleicos
CL2017002939A1 (es) Composiciones farmacéuticas tópicas
EA201990706A1 (ru) Фармацевтическая композиция
PE20150997A1 (es) Nanoparticulas terapeuticas que comprenden un agente terapeutico y metodos para realizarlas y usarlas
BR112017012706A2 (pt) formulações de sunitinibe e métodos para uso destas no tratamento de transtornos oculares
BR112017006957A2 (pt) formulações farmacêuticas para a liberação por via oral de fármacos do tipo de peptídeo ou proteína
BR112016018673A2 (pt) Composições de sistemas de distribuição de nanoemulsão
CY1117869T1 (el) Φαρμακοτεχνικες μορφες για απο του στοματος απελευθερωση προσροφητικων στο εντερο
MX2019003467A (es) Formulaciones y metodos para la administracion vaginal de antiprogestinas.
CO2017012670A2 (es) Unidad de dosificación orodispersable que contiene un componente estetrol
IN2013MN02384A (es)
AR091006A1 (es) Formulaciones de testosterona proliposomal
AR076722A1 (es) Conjunto para un dispositivo para l a entrega de farmacos y dispositivo para la entrega de farmacos
AR088585A1 (es) Un medicamento para tratar la enfermedad del ojo anterior
CO7151496A2 (es) Agentes terapeúticos para administración subcutánea optimizados
BR112013004570A2 (pt) emulsão do tipo água-em-óleo para tratar uma doença do olho
MX2017013636A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde diferentes particulas.
MX2019015927A (es) Composiciones para administración de fármacos y métodos de uso de las mismas.
NI201000181A (es) Utilización de dronedarona para preparar un medicamento para el tratamiento de pacientes con arritmia y que tienen un incremento del nivel de creatinina debido a la administración de dronedarona.
EA201890703A1 (ru) Коллоидные частицы, предназначенные для применения в медицине
WO2014075203A1 (es) Nanopartículas con polímero biodegradable y biocompatible plga cargadas con el fármaco de uso humano pentoxfilina
BR112017019364A2 (pt) dispersões sólidas